Technology ID
TAB-3440
Monoclonal Antibody that Detects a Subclass of Dog IgG—for Diagnostic and Research Applications
E-Numbers
E-001-2021-0
Lead Inventor
Priest, Jeffrey (CDC)
Co-Inventors
Roy, Sharon (CDC)
Cama, Vitaliano (CDC)
Applications
Research Materials
Diagnostics
Consumer Products
Therapeutic Areas
Infectious Disease
Immunology
Development Stages
Pre-Clinical (in vitro)
Research Products
Antibodies
Lead IC
CDC
ICs
CDC
CDC and collaborating researchers have developed a new monoclonal antibody that recognizes canine IgG (likely IgG4 subclass). This anti-dog IgG reagent could be used to detect antibody reactions to a variety of antigens and has potential use in a wide variety of diagnostic or research applications.
The team used the published method of Mazza et al. (1993) to isolate a canine IgG fraction (peak Z) and used that fraction to create a new monoclonal antibody. The new monoclonal antibody appears to specifically recognize a particular subclass of canine IgG (likely IgG4) with high reactivity and low background. Very few commercial reagents are available for the detection of canine IgG antibodies, and none react as well as the newly created monoclonal antibody.
The team used the published method of Mazza et al. (1993) to isolate a canine IgG fraction (peak Z) and used that fraction to create a new monoclonal antibody. The new monoclonal antibody appears to specifically recognize a particular subclass of canine IgG (likely IgG4) with high reactivity and low background. Very few commercial reagents are available for the detection of canine IgG antibodies, and none react as well as the newly created monoclonal antibody.
Commercial Applications
- Anti-dog IgG reagent to detect antibody reactions to a variety of antigens
- Use in a wide variety of diagnostic or research applications
- Use to develop or improve diagnostic or research methods that require canine antibody detection
- IgG4 responses are typically observed during parasitic infections with roundworms such as heartworm and hookworm
Competitive Advantages
- Improved detection of canine IgG antibodies over the limited, currently available commercial reagents
- Specific recognition of a particular subclass of canine IgG (likely IgG4) with high reactivity and low background
Licensing Contact: